These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25812672)

  • 21. [New developments in hormone replacement therapy].
    Winter R; Haller U; Hepp H
    Gynakol Geburtshilfliche Rundsch; 2003 Oct; 43(4):229-30. PubMed ID: 14526154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
    ; Beral V; Gaitskell K; Hermon C; Moser K; Reeves G; Peto R
    Lancet; 2015 May; 385(9980):1835-42. PubMed ID: 25684585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone replacement therapy and ovarian cancer risk--any news?
    Riman T
    Acta Obstet Gynecol Scand; 2007; 86(9):1032-4. PubMed ID: 17712640
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk?
    Rozenberg S; Antoine C; Vandromme J; Fastrez M
    Climacteric; 2015; 18(4):448-52. PubMed ID: 25958744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risks, benefits and costs of hormone replacement therapy in menopause].
    Gaspard U
    Rev Med Liege; 1998 May; 53(5):298-304. PubMed ID: 9689887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.
    Lee AW; Ness RB; Roman LD; Terry KL; Schildkraut JM; Chang-Claude J; Doherty JA; Menon U; Cramer DW; Gayther SA; Risch H; Gentry-Maharaj A; Goodman MT; Modugno F; Eilber U; Moysich KB; Berchuck A; Rossing MA; Jensen A; Wicklund KG; Cushing-Haugen KL; Hogdall E; Rudolph A; Thompson PJ; Wilkens LR; Kjaer SK; Carney ME; Stram DO; Ramus SJ; Wu AH; Pike MC; Pearce CL;
    Obstet Gynecol; 2016 May; 127(5):828-836. PubMed ID: 27054934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.
    Pearce CL; Chung K; Pike MC; Wu AH
    Cancer; 2009 Feb; 115(3):531-9. PubMed ID: 19127543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormone replacement therapy in menopause and risk of breast cancer].
    Fournier A; Hill C; Clavel-Chapelon F
    Bull Cancer; 2003 Oct; 90(10):821-31. PubMed ID: 14706912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen-progestogen replacement therapy and ovarian cancer: an update.
    La Vecchia C
    Eur J Cancer Prev; 2006 Dec; 15(6):490-2. PubMed ID: 17106327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.
    Yang HP; Anderson WF; Rosenberg PS; Trabert B; Gierach GL; Wentzensen N; Cronin KA; Sherman ME
    J Clin Oncol; 2013 Jun; 31(17):2146-51. PubMed ID: 23650423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
    Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
    Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Menopausal hormonal therapy and breast cancer.].
    Bakhidze EV; Belyaeva AV; Berlev IV; Anisimov VN; Belyaev AM
    Adv Gerontol; 2021; 34(2):277-286. PubMed ID: 34245512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.